Common supplement SAMe tested to block liver cancer in fatty liver patients
NCT ID NCT07495995
First seen Apr 23, 2026 · Last updated May 07, 2026 · Updated 3 times
Summary
This study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo daily for 12 months. Researchers will measure changes in a blood test that predicts liver cancer risk, and check for side effects. This is an early-phase trial to see if SAMe is worth studying further for this purpose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.